Psychedelic clinics to offer $20,000 treatments for severe depression from July
Question: Is $20,000 a fair fee to charge those with severe depression for a treatment many regard as experimental?
Does it exploit their desperation for a fix to an illness that blights their world so deeply?
Back in February, in one of the most controversial decisions in its history, the TGA decided to reclassify psychedelic substances as S8s, making them a therapeutic option for psychiatrists outside a clinical trial.
That decision, the first of its kind anywhere in the world, means that from 1 July MDMA can be used to treat PTSD, and psilocybin as a last resort for treatment-resistant depression.